Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

52.95 +0.96 (+1.85%)

Official Closing Price Updated: 6:30 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

44 45 Next >

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection ↗

February 26, 2024

Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising...

Via Benzinga

3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List ↗

February 22, 2024

Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.

Via InvestorPlace

Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report ↗

February 22, 2024

The company unexpectedly came in with fourth-quarter earnings that beat projections.

Via Investor's Business Daily

Looking Into GSK's Recent Short Interest ↗

February 12, 2024

Via Benzinga

Recap: GSK Q4 Earnings ↗

January 31, 2024

Via Benzinga

Earnings Outlook For GSK ↗

January 30, 2024

Via Benzinga

A Look Into GSK Inc's Price Over Earnings ↗

January 26, 2024

Via Benzinga

Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus ↗

February 21, 2024

Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024.

Via Benzinga

3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth ↗

February 21, 2024

Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.

Via InvestorPlace

Dividend Income Update January 2024 ↗

February 15, 2024

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio

Via Talk Markets

Why Is Moderna Stock Trading Lower Today? ↗

February 09, 2024

Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.

Via Benzinga

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

February 08, 2024

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally

From Alector, Inc.

Via GlobeNewswire

23andMe Reports Third Quarter Fiscal 2024 Financial Results

February 07, 2024

Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473

From 23andMe, Inc.

Via GlobeNewswire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

February 07, 2024

From Alector, Inc.

Via GlobeNewswire

Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?' ↗

February 06, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).

Via Benzinga

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

February 06, 2024

From GSK plc

Via Business Wire

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗

February 06, 2024

Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.

Via InvestorPlace

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option ↗

February 02, 2024

Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.

Via Benzinga

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

What's Going On With GSK Stock Today? ↗

February 01, 2024

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

Via Benzinga

Topics Lawsuit

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗

January 31, 2024

Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.

Via Investor's Business Daily

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine ↗

January 31, 2024

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

Via Benzinga

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗

January 30, 2024

Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.

Via Benzinga

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

January 24, 2024

From Elegen

Via Business Wire

GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M ↗

January 17, 2024

GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.